This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More
A team of New York University (NYU) chemists and physicists have unlocked how cells build and grow tiny, dynamic droplets known as biomolecular condensates. For the first time, scientists measured the protein content and growth dynamics of individual biomolecular condensates without disturbing them, gaining insights that may… Read More
Scientists have obtained new data on many of the proteins responsible for regulating the cell cycle – a sequence of molecular events that culminates in the production of two daughter cells. A dysregulated cell cycle is a hallmark of several diseases, including cancer. This information will not only provide the… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More
Significant changes in the molecular characteristics of tumour samples occur within as little as 10 minutes after surgical removal, a new study led by Indivumed Therapeutics has revealed. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and… Read More
Zhijian ‘James’ Chen, Professor of Molecular Biology and Director of the Center for Inflammation Research at UT Southwestern Medical Center, has been awarded the Albert Lasker Basic Medical Research Award for his discovery of the cGAS enzyme, which senses invading pathogens and triggers the body’s innate immune system. … Read More
Dr Benedict Cross, CTO, PhoreMost, explores the drug discovery potential that targeted protein degradation (TPD) offers. The ubiquitin proteasome pathway (UPP) has been a subject of interest for therapeutic intervention since the first proteasome inhibitors to treat multiple myeloma were developed and approved in 2015. The… Read More
Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More
In a first for 2024, DDW will be hosting the SLAS Ignite Theater track on the theme of ‘Innovation & technology: from lab to patient’. It will take place at SLAS2024 in Boston on 5 and 6 February 2024 and is co-sponsored by… Read More
Listen to this article on the DDW Podcast: Dr Luke Clifton, Instrument Scientist at ISIS Neutron and Muon Source, explains the molecular mechanism behind antibiotics. Since the initial large-scale production and widespread use of antibiotics in the 1940s there has been a continual… Read More
AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division. BioPharmics has… Read More
A molecular machine, which plays an essential ‘cargo’ role in controlling the delivery of proteins to the surface of human cells has been identified using artificial intelligence (AI). The research has shown how manipulating this process could treat or prevent disease, with implications for SARS-CoV-2, human… Read More
Listen to this article on the DDW Podcast: José Mejía Oneto, PhD, Founder and CEO at Shasqi, discusses the potential of chemistry to engineer biology to improve the effectiveness of human therapeutics and revolutionise the treatment of disease. What if we could control… Read More
US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted… Read More
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did… Read More
This is the latest episode of the free DDW podcast, “Painting a picture of the lab of the future”. It covers two articles written for the exclusive DDW & SLAS2022 supplement published in Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Perspective: education and lab automation”… Read More
